Written and maintained by CASRAI Editorial Board
Published
Reader task: Understand the clinical mechanism, FDA device classification, specialized foam dressing architecture, and hospital procurement requirements for Veraflo negative pressure wound therapy with instillation.
This page describes products and general use; it is not medical advice.
On this page
Short answer
Veraflo is an advanced negative pressure wound therapy system that integrates automated instillation and dwell time of topical solutions (NPWTi-d). Designed for hospital and acute care settings, it delivers volumetric wound irrigation, allows solutions to dwell, and removes fluids and bioburden under negative pressure to accelerate granulation tissue formation and assist in wound cleansing.
Definition and scope
Developed by KCI and maintained under 3M Health Care (now Solventum), Veraflo (formally V.A.C. Veraflo™ Therapy) delivers negative pressure wound therapy with instillation and dwell time (NPWTi-d). Unlike conventional negative pressure units that only apply suction, Veraflo provides automated cycles of topical fluid instillation, dwell soak, and sub-atmospheric fluid extraction.
Veraflo devices and dressing kits operate under FDA 510(k) clearances, including K221585, K211521, K160451, and K103156. The system is classified under 21 CFR 878.4780 as a Class II medical device under Product Code OMP (“Negative Pressure Wound Therapy Powered Suction Pump”), assigned to General and Plastic Surgery.
Veraflo is indicated for acute and chronic wounds with heavy bioburden, including dehisced surgical wounds and ulcers. Clinicians consult clinical frameworks like a wound care pocket guide to assess wound bed viability before initiating therapy.
How it works or how it is used in practice
Operated through the V.A.C. Ulta™ Therapy Unit, Veraflo automates three cyclical phases:
- Automated Instillation: The unit infuses a programmed volume of topical solution into the sealed dressing via an instillation cassette and tubing pad.
- Controlled Dwell Time: Suction pauses, allowing fluid to dwell without negative pressure (typically 10 to 20 minutes) to loosen slough and bioburden.
- Negative Pressure Evacuation: Continuous suction resumes (typically -125 mmHg for 2 to 3.5 hours) to evacuate fluid, exudate, and debris into a collection canister.
Sterile 0.9% normal saline serves as the standard instillation solution. Compatible antiseptics like hypochlorous acid (evaluated in our review of Puracyn wound cleanser ingredients and regulatory status) may be prescribed. Manufacturer instructions for use (IFU) strictly contraindicate alcohol-based solutions, hydrogen peroxide, and Octenisept® due to tissue necrosis and foam degradation risks.
Health technology appraisals confirm clinical efficacy. The UK National Institute for Health and Care Excellence published Medical Technologies Guidance 54 (NICE MTG54 / HTG566), concluding that Veraflo NPWTi-d accelerates granulation tissue formation, reduces surgical debridements, and shortens hospital stays compared to standard wound care.
Types or related concepts
Veraflo utilizes reticulated open-cell polyurethane foam dressings engineered with specific fluid-distribution geometries. The table below compares Veraflo dressings with conventional negative pressure foam and alternative wound technologies from FDA clearance records and manufacturer specifications.
| Technology / Dressing | Material and Architecture | Primary Mechanism | Representative SKUs / Coding | Care Setting and Context |
|---|---|---|---|---|
| V.A.C. Veraflo™ Dressing Kit | Reticulated open-cell polyurethane foam with through-holes | Rapid fluid saturation during instillation and uniform negative pressure distribution | ULTVFL05SM, ULTVFL05MD, ULTVFL05LG; HCPCS A6550 | Inpatient facilities; clean-granulating or lightly sloughy wounds requiring cleansing |
| V.A.C. Veraflo Cleanse Choice™ | Tri-layer foam system with 1 cm contact layer through-holes | Mechanical loosening and extraction of thick fibrinous exudate and slough | ULTVCC05MD, VFCCC05MD, VFCCC05LG; HCPCS A6550 | Inpatient surgical units; heavily contaminated wounds and viscous slough |
| Standard V.A.C.® GranuFoam™ | Hydrophobic reticulated polyurethane foam (400–600 μm pores) | Continuous or intermittent negative pressure drainage without fluid instillation | M8275051; HCPCS A6550 | Inpatient and outpatient; standard negative pressure therapy without fluid delivery |
| Silicone Foam Wound Dressing | Polyurethane foam absorbent core with soft silicone adhesive face | Passive vertical absorption and vapor transmission without pump suction | Cross-walk to silicone foam wound dressings; HCPCS A6212–A6214 | Outpatient, clinic, and home care; exuding wounds without cavity vacuum |
| Hydrophobic DACC Dressing | Monofilament acetate fabric coated with dialkylcarbamoyl chloride | Binds bacteria through physical hydrophobic interactions without fluid delivery | Cross-walk to Cutimed Sorbact dressings; HCPCS A6206 | Outpatient and post-acute; managing bioburden without suction devices |
| Closed-Suction Surgical Drain | Perforated silicone or PVC tubing with bulb or spring vacuum reservoir | Continuous fluid evacuation from surgical dead space | Cross-walk to surgical drain types and materials; CPT 10140 / HCPCS A4326 | Post-surgical inpatient recovery; cavity drainage without wound instillation interface |
Where it matters for labs, clinics or supply decisions
For hospital supply chain teams, clinical trial coordinators, and procurement staff, Veraflo imposes specific operational, coding, and clinical controls:
- Inpatient Facility Requirement: The V.A.C. Ulta unit and Veraflo dressings are cleared exclusively for acute hospital care; the manufacturer IFU explicitly states the system is not intended for home use. Discharge planners must schedule a transition to ambulatory negative pressure pumps prior to patient discharge.
- Consumable Line Coordination: Operating Veraflo requires three synchronized disposable lines: the dedicated Veraflo foam dressing kit, an instillation cassette with fluid delivery line, and a compatible collection canister. Depletion of any component halts therapy.
- HCPCS and Procedure Coding: Billing follows HCPCS Level II codes
E2402(electrical pump),A6550(wound care set including dressings and tubing), andA7000(canister). Outpatient application utilizes CPT97605(≤ 50 cm²) or97606(> 50 cm²). - Foam Piece Accounting: Inpatient safety guidelines mandate documenting the number of foam pieces placed into a wound. Clinical staff must reconcile the count during dressing removal to prevent retained foreign bodies.
- Contraindication Protocols: Veraflo dressings must never contact exposed blood vessels, organs, anastomotic sites, or nerves. Untreated osteomyelitis, unexplored fistulas, and intact necrotic eschar are strict contraindications. Delivering solutions into thoracic or abdominal cavities is prohibited due to hypothermia and fluid retention hazards.
Common misunderstandings
Common clinical and procurement misconceptions include:
- Confusing Veraflo with Standard NPWT: Standard NPWT only extracts exudate. Veraflo incorporates automated fluid delivery and timed dwell soaking prior to suction. Conventional pumps cannot perform instillation cycles.
- Assuming Veraflo Can Transition Home: The V.A.C. Ulta device is restricted to facility care. Discharged patients must transition to outpatient-cleared negative pressure pumps without instillation.
- Treating Instillation as Systemic Drug Delivery: Veraflo provides localized topical wound cleansing. It is not cleared for systemic delivery of antibiotics or pharmacologic therapeutics.
- Substituting Standard Foam into Instillation Circuits: Standard GranuFoam lacks the through-hole distribution architecture required for uniform fluid instillation. Substituting standard foam risks fluid pooling and peri-wound maceration.
Frequently asked questions
What is Veraflo therapy?
Veraflo therapy is an automated wound treatment combining negative pressure wound therapy with automated instillation and dwell time of topical solutions (NPWTi-d). It cleanses wounds by soaking debris during programmed dwell windows and evacuating fluid under sub-atmospheric pressure.
Can Veraflo therapy be used at home?
No. The V.A.C. Ulta system that delivers Veraflo therapy is cleared solely for hospital and clinical facility settings. It is not indicated for home care or ambulatory self-management.
What solutions can be instilled with Veraflo?
Sterile 0.9% normal saline is the primary instillation fluid. Clinicians may also order compatible topical antiseptics. Solutions with alcohol, hydrogen peroxide, or Octenisept are contraindicated by the manufacturer.
What HCPCS billing codes apply to Veraflo equipment?
Veraflo equipment maps to HCPCS E2402 for the pump, A6550 for dressing and tubing sets, and A7000 for collection canisters. Outpatient application is coded under CPT 97605 or 97606 based on wound area.
How does Veraflo Cleanse Choice differ from standard Veraflo foam?
Standard Veraflo foam is a reticulated polyurethane foam designed for uniform fluid dispersion. Veraflo Cleanse Choice features a contact layer with 1 cm mechanical through-holes specifically engineered to loosen and extract thick slough and viscous exudate.
Sources
- United States Food and Drug Administration (FDA), 510(k) Premarket Notification K221585, “3M V.A.C. Veraflo Cleanse Choice Dressing Kit” — https://api.fda.gov/device/510k.json?search=k_number:K221585 (read November 10, 2026).
- United States Food and Drug Administration (FDA), 510(k) Premarket Notification K211521, “3M Veraflo Cleanse Choice Complete Dressing Kit” — https://api.fda.gov/device/510k.json?search=k_number:K211521 (read November 10, 2026).
- United States Food and Drug Administration (FDA), Product Classification Database, 21 CFR 878.4780, Product Code OMP — https://api.fda.gov/device/classification.json?search=product_code:OMP (read November 10, 2026).
- National Institute for Health and Care Excellence (NICE), Medical Technologies Guidance 54 (MTG54 / HTG566), “The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal” — https://www.nice.org.uk/guidance/mtg54 (published January 2021, read November 10, 2026).
- 3M Health Care / Solventum, “V.A.C. Ulta™ Negative Pressure Wound Therapy System and V.A.C. Veraflo™ Therapy Safety Information and Instructions for Use” — https://www.solventum.com (read November 10, 2026).
- Centers for Medicare & Medicaid Services (CMS), Healthcare Common Procedure Coding System (HCPCS) Level II DME Codes E2402, A6550, and A7000 — https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system (read November 10, 2026).







